| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
1 Istituto di Endocrinologia ed Oncologia Sperimentale del CNR "G.Salvatore", c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita' Federico II, Naples, Italy; 2 Endocrinology and Metabolism Division, University of California at Los Angeles School of Medicine, Los Angeles, California; and 3 Instituto de Biologia Molecular y Celular del Cancer, Centro de Investigacion del Cancer (Consejo Superior de Investigaciones Científicas-Universidad de Salamanca), University of Salamanca, Salamanca, Spain
Requests for reprints: Massimo Santoro, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Medical School, University "Federico II" of Naples, via Sergio Pansini 5, 80131 Naples, Italy. Phone: 39-081-7463056; Fax: 39-081-7463037; E-mail: masantor{at}unina.it.
RET/papillary thyroid carcinoma (PTC) oncoproteins result from the in-frame fusion of the RET receptor tyrosine kinase with protein dimerization motifs encoded by heterologous genes. Here, we show that RET/PTC1 activates the Rap1 small GTPase. The activation of Rap1 was dependent on the phosphorylation of RET Tyr1062. RET/PTC1 recruited a complex containing growth factor receptor binding protein 2associated binding protein 1 (Gab1), CrkII (v-crk sarcoma virus CT10 oncogene homologue II), and C3G (Rap guanine nucleotide exchange factor 1). By using dominant-negative and small interfering duplex (small interfering RNA) oligonucleotides, we show that RET/PTC1mediated Rap1 activation was dependent on CrkII, C3G, and Gab1. Activation of Rap1 was involved in the RET/PTC1mediated stimulation of the BRAF kinase and the p42/p44 mitogen-activated protein kinases. Proliferation and stress fiber formation of RET/PTC1expressing PC Cl 3 thyroid follicular cells were inhibited by the dominant-negative Rap1(N17) and by Rap1specific GTPase-activating protein. Thus, Rap1 is a downstream effector of RET/PTC and may contribute to the transformed phenotype of RET/PTCexpressing thyrocytes. [Cancer Res 2007;67(1):38190]
This article has been cited by other articles:
![]() |
F. Lezoualc'h Epac in melanoma: a contributor to tumor cell physiology? Focus on "Epac increases melanoma cell migration by a heparin sulfate-related mechanism" Am J Physiol Cell Physiol, October 1, 2009; 297(4): C797 - C799. [Full Text] [PDF] |
||||
![]() |
D. Hochbaum, K. Hong, G. Barila, F. Ribeiro-Neto, and D. L. Altschuler Epac, in Synergy with cAMP-dependent Protein Kinase (PKA), Is Required for cAMP-mediated Mitogenesis J. Biol. Chem., February 22, 2008; 283(8): 4464 - 4468. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. de Martimprey, J.-R. Bertrand, A. Fusco, M. Santoro, P. Couvreur, C. Vauthier, and C. Malvy siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma Nucleic Acids Res., January 17, 2008; 36(1): e2 - e2. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mariggio, B. M. Filippi, C. Iurisci, L. K. Dragani, V. De Falco, M. Santoro, and D. Corda Cytosolic Phospholipase A2{alpha} Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells Cancer Res., December 15, 2007; 67(24): 11769 - 11778. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dremier, M. Milenkovic, S. Blancquaert, J. E. Dumont, S. O. Doskeland, C. Maenhaut, and P. P. Roger Cyclic Adenosine 3',5'-Monophosphate (cAMP)-Dependent Protein Kinases, But Not Exchange Proteins Directly Activated by cAMP (Epac), Mediate Thyrotropin/cAMP-Dependent Regulation of Thyroid Cells Endocrinology, October 1, 2007; 148(10): 4612 - 4622. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |